Medium materiality6/10
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Goldman Sachs raised CRSP price target to $55 from $48.
- Target: $55
- Posted price: $52.22
- Analyst firm: Goldman Sachs
Key facts
- 01
Target: $55
- 02
Posted price: $52.22
- 03
Analyst firm: Goldman Sachs
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.